Camurus ABCAMRF 81 EV-to-EBIT is 32.53 as of Jul. 11, 2026. GuruFocus rates CAMRF with a GF Score™ of 81/100 and a GF Value™ of $83.45 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 366 Biotechnology companies, Camurus AB ranks worse than 73.22% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Camurus AB's Enterprise Value for the quarter that ended in Mar. 2026 was $2,868.8 Mil.
Camurus AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $92.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB EV-to-EBIT Related Terms
Camurus AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Camurus AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Camurus AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Camurus AB's EV-to-EBIT falls into.
Camurus AB's current Enterprise Value is $3,003.4 Mil.
Camurus AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $92.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Camurus AB (CAMRF) has a EV-to-EBIT of 32.53 as of Jul. 11, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Camurus AB and its competitors. According to the industry distribution chart, Camurus AB ranks #268 out of 366 companies in the Biotechnology industry, placing it in the top 73.2%.
Is Camurus AB's EV-to-EBIT too high?
Camurus AB's current EV-to-EBIT is 32.53. The Biotechnology industry median EV-to-EBIT is 15.02. Camurus AB's value of 32.53 is 116.6% above this industry median. Based on the distribution chart, Camurus AB ranks #268 out of 366 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #268 out of 366 companies for EV-to-EBIT. This places Camurus AB in the lower half of its industry. The industry median EV-to-EBIT is 15.02. Camurus AB's value of 32.53 is 116.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.02, based on 366 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current EV-to-EBIT of 32.53 is 116.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Camurus AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current EV-to-EBIT is 32.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $83.45, compared to a current price of $60.00 — trading 28.1% below its estimated fair value. The current EV-to-EBIT is 32.53 and 116.6% above the Biotechnology industry median of 15.02. Camurus AB's overall GF Score™ is 81/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Camurus AB (CAMRF), the current EV-to-EBIT is 32.53 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $60.00 is trading 28.1% below its estimated GF Value™ of $83.45.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
EV-to-EBIT: 32.53
GF Value™: $83.45 vs. price of $60.00 (28.1% below fair value)
Industry Position: 116.6% above the Biotechnology median (#268 of 366)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
